Certara Introduces Pre-clinical Safety Store to Capture and Validate File-based Study Data in a CDISC-SEND Database
Product will serve as a data source for D360, supporting ongoing study monitoring and cross-study analyses
Certara™, the leading global technology-enabled drug development and drug safety consultancy, announced today the launch of its Pre-clinical Safety Store (PCSS). A companion product to D360, Certara’s integrated solution for the query, analysis and visualization of drug discovery and development data, PCSS enables the capture and validation of file-based pre-clinical study data in a CDISC-SEND architected database, meeting FDA recommendations for standardization of data formats for study data in regulatory submissions.
Pharmaceutical customers who pair PCSS with D360 will be able to access pre-clinical study data from contract research organizations (CROs) in minutes, in a consistent format, for study monitoring and cross-study analysis. PCSS also offers a terminology mapping tool that provides a consistent view of study data from multiple sources.
PCSS was developed in collaboration with D360 customers to address specific challenges that they were facing, such as CROs supplying their data in different file forms and using different names for the same test. PCSS uploads study data files into a SEND-based data system so that the information can be readily queried and analyzed by D360. PCSS also standardizes the naming convention used to match either CDISC-SEND controlled terminology or a customer’s own.
“Capturing study data using PCSS allows real-time study monitoring; it takes just minutes to upload and query the data and eliminates hours of complex file manipulation. That, in turn, permits rapid decision making about ongoing studies,” said Certara Chief Technology Officer Jonathan Feldmann. “Furthermore, by facilitating trend analysis of past studies, PCSS helps improve study design and drug development research.”
Certara will be demonstrating PCSS in booth #325 at the Bio-IT World Conference & Expo in Boston, MA from April 29-May 1.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
